1.    Stivala S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Chiu S, Keller M, Kleppe M, Hilpert M, Buser A, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC. Targeting cell non-autonomous MAPK activation to increase therapeutic efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 Mar4;130:1596-1611. PMID: 30730307. DOI: 10.1172/JCI98785

2.    Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, Maher R, Pronier E, Meyer SC, Garrett-Bakelman FE, Tallman M, Melnick A, Levine RL, Shih AH. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell. 2018 Jan 8;33(1):44-59.e8. Epub 2017 Dec 21. PMID: 29275866. DOI: 

3.    Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD. Mediator kinase phosphorylation of STAT1 S727 is required for neoplasms with JAK-STAT activation. Ebiomedicine. 2017 Dec 26:112-125. Epub 2017 Nov 21. PMID: 29239838. DOI:

4.    Stivala S, Gobbato S, Infanti L, Reiner MF, Bonetti N, Meyer SC, Camici GG, Lüscher TF, Buser A, Beer JH. In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica. 2017 Dec;102(12):e504-e505. PMID: 29192132. DOI:

5.    Meyer SC. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017 Aug;31(4):627-42. Epub 2017 May 13. PMID: 28673392. DOI:

6.    Meyer SC, SteinmannE, Lehmann T, Muesser P, Passweg JR, Skoda RC, Tsakiris DA. Anti-platelet factor 4/heparin antibody formation occurs endogenously and at unexpected high frequency in polycythemia vera. Biomed Res Int. 2017; 2017:9876819. Epub 2017 Jun 18. PMID: 28698883.

7.    Stivala S, Gobbato S, Infanti L, Reiner MF, Bonetti N, Meyer SC, Camici GG, Lüscher TF, Buser A, Beer JH. Amotosalen/UVA Pathogen Reduction Technology Induces Platelet Apoptosis and Accelerates Platelet Clearance. Haematologica. 2017 Oct;102(10)1650-1660. Epub 2017 Jul 20. PMID: 28729303.

8.    Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Vannucchi A, Guglielmelli P, Milosevic J, Kralovics R, Dirnhofer S, Orkin SH, Skoda RC. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.  J Exp Med. 2016 Jul 25;213(8):1479-96. Epub 2016 Jul11. PMID: 27401344.

9.    Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, Hao-Shen H, Romanet V, Murakami M, Radimerski T, Dirnhofer S, Skoda RC. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016 Aug 11;128(6):839-51. Epub 2016 Jun 10. PMID: 27288519.

10.  Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova O, Rapaport F, Ke Xu, Manova K, Pankov D, O’Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K,  Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Damassa E, Romanet V, Doelemeyer A, Zender M, Heinlein M, Rampal R, Singer R, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28. PMID: 26175413.

11.  Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, Bhagwat N, Marubayashi S, Levine RL. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood. 2014 Oct 2;124(14):2280-4. Epub 2014 Aug 12. PMID: 25115888.

12.  O’Meara A, Holbro A, Meyer SC, Martinez M, Medinger M, Buser A, Halter J, Heim D, Gerull S, Bucher C, Rovo A, Kuhne T, Tichelli A, Gratwohl A, Stern M, Passweg JR. Forty years of hematopoietic stem cell transplantation: a review of the Basel experience. Swiss Med Wkly. 2014 Feb 24;144:w13928. PMID: 24567259.

13.  Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukemia. Lancet Oncol. 2014 Aug;15(9):e382-94. PMID: 25079101.

14. Meyer SC, Levine RL. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res. 2014 Apr 15;20(8):2051-9. Epub 2014 Feb 28. PMID: 24583800.

15.  Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013 Nov 27;5(4):1047-59. Epub 2013 Nov 21. PMID: 24268771.